Breaking News Instant updates and real-time market news.

PDCO

Patterson Companies

$22.32

0.51 (2.34%)

, XEC

Cimarex Energy

$90.63

0.72 (0.80%)

09:55
06/19/18
06/19
09:55
06/19/18
09:55

Early notable gainers among liquid option names on June 19th

Notable gainers among liquid option names this morning include Patterson Companies (PDCO) $22.29 +0.47, Cimarex Energy (XEC) $91.70 +1.78, CVS Health (CVS) $69.01 +1.28, Mallinckrodt (MNK) $19.63 +0.34, and Colgate Palmolive (CL) $64.34 +1.04.

PDCO

Patterson Companies

$22.32

0.51 (2.34%)

XEC

Cimarex Energy

$90.63

0.72 (0.80%)

CVS

CVS Health

$68.52

0.79 (1.17%)

MNK

Mallinckrodt

$19.64

0.36 (1.87%)

CL

Colgate-Palmolive

$64.10

0.8 (1.26%)

  • 21

    Jun

  • 22

    Aug

PDCO Patterson Companies
$22.32

0.51 (2.34%)

03/08/18
LEHM
03/08/18
INITIATION
Target $23
LEHM
Underweight
Patterson Companies initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Patterson Companies with an Underweight rating and $23 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
04/04/18
UPGRADE
Target $80

Outperform
Henry Schein upgraded to Outperform at Leerink
As previously reported, Leerink analyst David Larsen upgraded Henry Schein (HSIC) to Outperform from Market Perform as he believes investor concerns around Amazon (AMZN), the FTC complaint, and Patterson Companies' (PDCO) recent Q3 results are overdone. Based on a recent MEDACorp survey, the analyst believes that Henry Schein ranks #1 in overall quality of service as considered by dental practices, vet offices, and physician groups. Larsen also raised his price target on Henry Schein shares to $80 from $75.
04/06/18
CHLM
04/06/18
UPGRADE
Target $28
CHLM
Buy
Patterson Companies upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Kevin Ellich upgraded Patterson Companies to Buy from Hold and raised his price target on the stock to $28 from $23, stating that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. He also sees limited downside from the current valuation and finds the 4.7% dividend yield attractive.
XEC Cimarex Energy
$90.63

0.72 (0.80%)

05/25/18
STFL
05/25/18
NO CHANGE
Target $180
STFL
Buy
Cimarex Energy price target raised to $180 after Ward County sale at Stifel
Stifel analyst Michael Scialla said he views Cimarex Energy's Ward County divestiture favorably as the implied acreage price exceeded his expectations and the deal improves "an already stout balance sheet." Scialla raised his price target on Cimarex to $180 from $175 following the deal announcement and keeps a Buy rating on the shares.
06/19/18
COWN
06/19/18
NO CHANGE
Target $130
COWN
Outperform
Cimarex Energy second half ramp fears overdone, says Cowen
Cowen analyst Charles Robertson said investor fears about the second half ramp at Cimarex Energy are overdone since the company has the firm capacity to achieve its 2018-2019 production growth and the company maintains a very strong balance sheet. Robertson reiterated his Outperform rating and raised his price target to $130 from $115 on Cimarex Energy shares.
06/11/18
JEFF
06/11/18
NO CHANGE
JEFF
Jefferies upgrades Cimarex to Buy, downgrades Oasis to Hold
Jefferies analyst Mark Lear upgraded Cimarex Energy (XEC) to Buy from Hold and raised his price target for the shares to $107 from $98. The analyst also downgraded Oasis Petroleum (OAS) to Hold from Buy with an unchanged price target of $14. Infrastructure constraints and wider regional basis have raised growth concerns across the Permian and driven stocks to "irrational valuations," Lear tells investors in a research note. Jefferies also raised its per-barrel Brent price forecast to $77 from $64 in 2018; to $75 from $60 in 2019; and to $70 from $65 in 2020. He notes shares of Cimarex now trade at "more than half a turn discount" to the group on consensus 2018 and 2020 EBITDA. Lear believes Cimarex's recent moves to address gas flow assurance in tandem with strategic partnerships in the Permian "provide some level of relative safety on the company's ability to maintain capital guidance." The analyst cites valuation for his downgrade of Cimarex following the stock's outperformance year-to-date.
06/11/18
JEFF
06/11/18
UPGRADE
Target $107
JEFF
Buy
Cimarex Energy upgraded to Buy from Hold at Jefferies
Jefferies analyst Mark Lear upgraded Cimarex Energy to Buy and raised his price target for the shares to $107 from $98.
CVS CVS Health
$68.52

0.79 (1.17%)

06/19/18
BOFA
06/19/18
NO CHANGE
BOFA
CVS Health added to US 1 List, Schlumberger removed at BofA/Merrill
06/13/18
LEER
06/13/18
NO CHANGE
LEER
AT&T, Time Warner approval positive for PBM-MDCO deals, says Leerink
Leerink analyst Ana Gupte says that the highly anticipated AT&T (T)-Time Warner (TWX) court decision is in favor of the companies and against the DoJ, "meaningfully increasing" the probability that the two vertical mega-mergers will close, namely Aetna (AET) and Express Scripts (ESRX), and CVS (CVS) and Cigna (CI).
06/13/18
DBAB
06/13/18
NO CHANGE
DBAB
CVS, Aetna deal on track to close in second half, says Deutsche Bank
After AT&T (T) won approval to acquire Time Warner (TWX), Deutsche Bank analyst Glen Santangelo continues to believe that CVS Health's (CVS) acquisition of Aetna (AET) is on track to close in the second half of 2018. He expects the favorable Time Warner ruling to further reduce the market spreads in both CVS, Aetna and Cigna (CI), Express Scripts (ESRX) from current levels. Shares of CVS represent a "compelling investment opportunity" at current valuation levels regardless of the regulatory outcome of the deal, Santangelo tells investors in a research note. He believes Cigna's acquisition of Express Scripts is also likely to close.
06/13/18
OPCO
06/13/18
NO CHANGE
OPCO
AT&T, Time Warner merger approval favorable for big healthcare deals, says Oppenheimer
Oppenheimer analyst Mohan Naidu notes that a federal judge approved AT&T's (T) purchase of Time Warner (TWX), without conditions, in a decision on a case brought by the DoJ in November, on insufficient proof of consumer or competitive harm, in what was widely considered a vertical merger. The closely watched trial was seen as a precedent case for CVS (CVS)-Aetna (AET) and Cigna (CI)-Express Scripts (ESRX), two vertical mergers in healthcare also currently under review by DoJ, he contends.
MNK Mallinckrodt
$19.64

0.36 (1.87%)

05/04/18
WELS
05/04/18
NO CHANGE
Target $15
WELS
Market Perform
Mallinckrodt price target lowered to $15 on stannsoporfin news at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Mallinckrodt to $15 from $17.50 after deciding to take stannsoporfin sales out of his model following the joint meeting of the FDA's GI Drugs Advisory Committee and Pediatric Advisory Committee, during which the panel overwhelmingly voted against the approval of stannsoporfin. He spoke with Mallinckrodt after the AdComm and the company said it is "disappointed" with the result and that a path forward for stannsoporfin will be evaluated to see if it makes sense to continue development, Maris noted. He maintains a Market Perform rating on Mallinckrodt shares.
05/04/18
MZHO
05/04/18
NO CHANGE
Target $13
MZHO
Neutral
Mallinckrodt likely to terminate jaundice program, says Mizuho
Mizuho analyst Irina Koffler expects Mallinckrodt to terminate its drug for severe jaundice after an FDA advisory panel recommended against approval. Termination could result in 15c-20c in earnings upside in 2018, Koffler tells investors in a research note. She views the news as a pipeline setback and keeps a Neutral rating on Mallinckrodt.
06/19/18
RHCO
06/19/18
NO CHANGE
Target $21
RHCO
Hold
Mallinckrodt price target raised to $21 from $14 at SunTrust
SunTrust analyst John Boris raised his price target on Mallinckrodt to $21 after the company reported positive Acthar interim data from its OL RA trial at Eular 2018. Boris says the efficacy data will help the company in its payer negotiations to stabilize Accthar and helps to de-risk his forecast for Acthar sales at $1.09B this year and $1.04B next year. The analyst keeps his Hold rating on Mallinckrodt, citing unpredictable long term growth path and declining Acthar volumes due to reimbursement issues.
05/09/18
LEHM
05/09/18
NO CHANGE
Target $12
LEHM
Underweight
Mallinckrodt price target lowered to $12 from $20 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Mallinckrodt to $12 and keeps an Underweight rating on the shares. While Stannsaporfin was not expected to be a big product commercially, its failure to get the FDA panel vote raises questions on Mallinckrodt's "R&D acumen," Tsao tells investors in a research note. Further, the analyst believes uncertainty on Acthar is likely to persist.
CL Colgate-Palmolive
$64.10

0.8 (1.26%)

05/24/18
BERN
05/24/18
NO CHANGE
Target $72
BERN
Market Perform
Colgate-Palmolive could be target for activists, says Bernstein
Bernstein analyst Ali Dibadj says his sum-of-the-parts analysis suggests Colgate-Palmolive's businesses, even beyond Oral Care, could be attractive to other owners, with areas for improvement more notably across Home Care and Pet Food. The analyst believes the company's stock could be a target for activists given its more realistic current valuation, with various levers at play to drive fundamental improvement and earnings growth. Dibadj reiterates a Market Perform rating and $72 price target on the shares.
05/25/18
ARGS
05/25/18
UPGRADE
ARGS
Buy
Colgate-Palmolive upgraded to Buy from Hold at Argus
05/25/18
05/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes PayPal is in the early stages of transforming from an online checkout company to a global payments platform. 2. Novartis (NVS) upgraded to Neutral from Underperform at Credit Suisse. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at Argus analyst John Eade saying the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. 4. Best Inc. (BSTI) upgraded to Buy from Neutral at Citi. 5. Loma Negra (LOMA) upgraded to Outperform from Market Perform at Itau BBA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
05/25/18
ARGS
05/25/18
UPGRADE
Target $72
ARGS
Buy
Colgate-Palmolive upgraded to Buy at Argus on valuation
As reported earlier, Argus analyst John Eade upgraded Colgate-Palmolive to Buy from Hold with a price target of $72. The analyst says the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. Eade further states that his $72 price target implies a multiple of 21-times forward earnings, which is still below the midpoint of the company's historical range.

TODAY'S FREE FLY STORIES

IWM

iShares Trust Russell 2000 Index Fund

$153.34

-1.625 (-1.05%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:44
10/19/18
10/19
15:44
10/19/18
15:44
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$153.34

-1.625 (-1.05%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$14.69

0.125 (0.86%)

15:40
10/19/18
10/19
15:40
10/19/18
15:40
Options
Call buyers in US Oil Fund as crude oil ticks higher »

Call buyers in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHP

Microchip

$67.36

-0.18 (-0.27%)

15:35
10/19/18
10/19
15:35
10/19/18
15:35
Options
Microchip put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

15:20
10/19/18
10/19
15:20
10/19/18
15:20
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CLF

Cleveland-Cliffs

$10.92

-0.55 (-4.80%)

15:18
10/19/18
10/19
15:18
10/19/18
15:18
Hot Stocks
Breaking Hot Stocks news story on Cleveland-Cliffs »

Cleveland-Cliffs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CLF

Cleveland-Cliffs

$10.86

-0.61 (-5.32%)

15:17
10/19/18
10/19
15:17
10/19/18
15:17
Hot Stocks
Breaking Hot Stocks news story on Cleveland-Cliffs »

Cleveland-Cliffs CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/19/18
10/19
15:17
10/19/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRX

AcelRx

$3.77

-0.38 (-9.16%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Hot Stocks
AcelRx responds to FDA advisory committee opinions on Dsuvia »

In response to opinions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLF

Cleveland-Cliffs

$10.89

-0.58 (-5.06%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Hot Stocks
Cleveland-Cliffs CEO, after berating analysts, says would handle call same way »

Cleveland-Cliffs CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$127.73

-6.91 (-5.13%)

, STMP

Stamps.com

$194.61

-3.18 (-1.61%)

15:08
10/19/18
10/19
15:08
10/19/18
15:08
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

SHOP

Shopify

$127.73

-6.91 (-5.13%)

STMP

Stamps.com

$194.61

-3.18 (-1.61%)

BLK

BlackRock

$402.46

2.59 (0.65%)

BX

Blackstone

$34.82

-0.45 (-1.28%)

JPM

JPMorgan

$108.18

0.05 (0.05%)

F

Ford

$8.45

-0.055 (-0.65%)

GS

Goldman Sachs

$227.49

2.55 (1.13%)

GOOGL

Alphabet Class A

$1,104.29

7.06 (0.64%)

GOOG

Alphabet

$1,095.63

7.73 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 13

    Dec

  • 26

    Feb

  • 03

    Mar

ET

Energy Transfer LP

$17.01

0.19 (1.13%)

15:04
10/19/18
10/19
15:04
10/19/18
15:04
Hot Stocks
Energy Transfer LP: Binding Expansion Open Season for Bakken Pipeline System »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$37.87

-0.12 (-0.32%)

15:00
10/19/18
10/19
15:00
10/19/18
15:00
Options
Active trading in Halliburton ahead of earnings »

Active trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FXI

iShares China Large-Cap ETF

$39.39

0.7 (1.81%)

14:50
10/19/18
10/19
14:50
10/19/18
14:50
Options
32K iShares Large Cap China Fund Dec 42 - 44 call spreads trade for 40c »

32K iShares Large Cap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEVO

Gevo

$3.61

-0.08 (-2.17%)

, GPRE

Green Plains

$17.97

-0.38 (-2.07%)

14:48
10/19/18
10/19
14:48
10/19/18
14:48
Periodicals
Marathon weighs sale of high-ethanol gas in Minnesota, Bloomberg says »

Marathon Petroleum (MPC)…

GEVO

Gevo

$3.61

-0.08 (-2.17%)

GPRE

Green Plains

$17.97

-0.38 (-2.07%)

PEIX

Pacific Ethanol

$2.03

-0.12 (-5.58%)

MPC

Marathon Petroleum

$74.24

-4.6 (-5.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

CMCSA

Comcast

$35.94

-0.01 (-0.03%)

, CMCSK

Comcast

$0.00

(0.00%)

14:46
10/19/18
10/19
14:46
10/19/18
14:46
OnTheFly
Box Office Battle: 'Halloween' opening to add to massive October »

Comcast (CMCSA, CMCSK)…

CMCSA

Comcast

$35.94

-0.01 (-0.03%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.76

-0.28 (-0.50%)

T

AT&T

$32.84

0.34 (1.05%)

FOX

21st Century Fox

$45.33

-0.13 (-0.29%)

FOXA

21st Century Fox

$45.62

-0.19 (-0.41%)

DIS

Disney

$118.42

2.16 (1.86%)

LGF.A

Lionsgate

$22.17

-0.03 (-0.14%)

LGF.B

Lionsgate

$20.72

-0.06 (-0.29%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

VIAB

Viacom

$33.30

-0.43 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOSL

Fossil

$19.00

-0.13 (-0.68%)

14:40
10/19/18
10/19
14:40
10/19/18
14:40
Options
Far upside call buying in Fossil »

Far upside call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.67

-1.28 (-0.83%)

, GOOG

Alphabet

$1,090.00

2.1 (0.19%)

14:33
10/19/18
10/19
14:33
10/19/18
14:33
Hot Stocks
#SocialStocks: Snap may be small enough to be acquired, YouTube suffers blackout »

Welcome to…

FB

Facebook

$153.67

-1.28 (-0.83%)

GOOG

Alphabet

$1,090.00

2.1 (0.19%)

GOOGL

Alphabet Class A

$1,098.63

1.4 (0.13%)

TWTR

Twitter

$28.71

-0.58 (-1.98%)

SNAP

Snap

$6.75

-0.06 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 03

    Mar

ABBV

AbbVie

$88.84

-1.1 (-1.22%)

14:22
10/19/18
10/19
14:22
10/19/18
14:22
Recommendations
AbbVie analyst commentary  »

AbbVie's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 02

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/19/18
10/19
14:17
10/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/19/18
10/19
14:16
10/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPC

Marathon Petroleum

$74.58

-4.26 (-5.40%)

, PEIX

Pacific Ethanol

$1.98

-0.17 (-7.91%)

14:15
10/19/18
10/19
14:15
10/19/18
14:15
Periodicals
Marathon weighs sale of high-ethanol gas in Minnesota, Bloomberg says »

Companies levered to…

MPC

Marathon Petroleum

$74.58

-4.26 (-5.40%)

PEIX

Pacific Ethanol

$1.98

-0.17 (-7.91%)

GPRE

Green Plains

$17.91

-0.44 (-2.40%)

GEVO

Gevo

$3.61

-0.08 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

DHI

D.R. Horton

$35.98

-1.41 (-3.77%)

14:15
10/19/18
10/19
14:15
10/19/18
14:15
Options
D R Horton put volume heavy and directionally bearish »

Bearish flow noted in D R…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ABBV

AbbVie

$89.28

-0.66 (-0.73%)

14:11
10/19/18
10/19
14:11
10/19/18
14:11
Hot Stocks
AbbVie CFO to retire in mid-2019 »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 02

    Nov

CP

Canadian Pacific

$200.85

1.58 (0.79%)

14:06
10/19/18
10/19
14:06
10/19/18
14:06
Hot Stocks
Canadian Pacific reports Toronto Stock Exchange acceptance of buyback plan »

Canadian Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.